Discover Guideview's Pharmaceutical articles! Stay informed about the latest news, policies, and scientific insights relevant to the pharmaceutical industry.
Sanofi 2025 h1 Performance Sanofi
Financial statementsSanofi reports strong 2025 H1 results with $21.8B revenue (+9.9%), driven by Dupixent sales hitting $8B and RSV antibody Beyfortus growing 79%. Rare disease drugs and BD deals also highlight growth momentum.
Sanofi 2025 q2 PerformanceSanofi
Financial statementsSanofi reports q2 2025 revenue of $21.9B, with Dupixent sales reaching $8B. Strong growth in immunology, vaccines, and new product launches. U.S. leads regional sales. Strategic acquisitions continue.
The Expanding Benefits of GLP-1 MedicinesDiabetes
SemaglutideDiscover the expanding benefits of GLP-1 drugs beyond diabetes and obesity, including improvements in heart, kidney, liver, joint, brain health, and more, as summarized by GLP-1 pioneer Daniel J. Drucker.
Adaptimmune Sells Four Core Cell TherapiesAdaptimmune
BiotechAdaptimmune Therapeutics sells four core cell therapies to US WorldMeds for $85M, ensuring continued patient access and advancing development of TECELRA, Lete-Cel, Afami-Cel, and Uza-Cel.
WuXi AppTec Delivers Best Ever Q2 PerformanceFinancial statements
WuXi AppTecWuXi AppTec reports its strongest Q2 ever in 2025, with revenue and profit seeing double-digit growth. Backed by a robust CRDMO model, the company raises its full-year guidance amid strong global demand for innovative drug development services.
Roche 2025 H1 Financial ReportRoche
Financial statementsRoche reports 7% growth in H1 2025, with Phesgo up 55% and Polivy up 46%. China revenue rises 9%. Strong gains in hematology, immunology, and ophthalmology offset legacy drug declines.
